Opioid Receptor Agonist

Opioid Receptor Agonists (153):

Cat. No.	Product Name	Effect	Purity

HY-123534

CYT-1010	Agonist	99.74%
CYT-1010 is a mu-opioid receptor agonist extracted from patent WO2013173730A2, with EC₅₀s of 13.1 nM and 0.0053 nM on beta-arrestin recruitment and inhibition of cAMP production, respectively.

HY-P3609

CR 665	Agonist	99.65%
CR 665 (JNJ 38488502) is a peripherally selective κ-opioid agonist. CR 665 can activate the kappa opioid receptor with EC₅₀ value of 10.9 nM. CR 665 can be used for the research of peripheral pain.

HY-P1170

N-terminally acetylated Leu-enkephalin	Agonist	99.49%
N-terminally acetylated Leu-enkephalin is the N-terminally acetylated form of Leu-enkephalin. Leu-enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.

HY-15997C

(±)-U-50488 hydrate hydrochloride	Agonist
(±)-U-50488 ((±)-Trans-(1R,2R)-U-50488) hydrate hydrochloride is a selective κ opioid receptor (KOR) agonist.

HY-B0418AS

Loperamide-d₆ hydrochloride	Agonist	99.07%
Loperamide-d₆ (hydrochloride) is a deuterium labeled Loperamide hydrochloride. Loperamide hydrochloride is an opioid receptor agonist for the treatment of diarrhea[1].

HY-107384

Asimadoline	Agonist	99.36%
Asimadoline (EMD-61753) is an orally active, selective and peripherally active κ-opioid agonist with IC₅₀s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS).

HY-14157

ADL-5747	Agonist	99.82%
ADL-5747 is a selective and orally active agonist of the δ-opioid receptor (DOR). By binding to the δ-opioid receptors, ADL-5747 activates these receptors, thereby playing a role in pain management pathways. ADL-5747 can be used for research into pain management mechanisms.

HY-12698

NNC 63-0532	Agonist	99.81%
NNC63-0532 is a novel non-peptide nociceptin receptor (ORL1) agonist, with EC₅₀s of 305?nM. NNC63-0532 plays important roles in many disorders such as pain, drug addiction.

HY-106147B

Frakefamide TFA	Agonist	99.18%
Frakefamide TFA is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system.

HY-13716A

Noscapine hydrochloride	Agonist	99.99%
Noscapine ((S,R)-Noscapine) hydrochloride is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine hydrochloride exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine hydrochloride disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine hydrochloride possesses anticancer, neuroprotective, anti-inflammatory activities, and can crosse the blood-brain barrier.

HY-P1481A

β-Casomorphin, human TFA	Agonist	99.67%
β-Casomorphin, human TFA (Human β-casomorphin 7 TFA) is an opioid peptide, acts as an agonist of opioid receptor.

HY-11051

JNJ-20788560	Agonist	98.00%
JNJ-20788560 is a selective and orally active delta opioid receptor agonist with an affinity of 2.0 nM for DOR (rat brain cortex binding assay). JNJ-20788560 also is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. JNJ-20788560 can be used for the research of the relief of inflammatory hyperalgesia.

HY-101582

ZT 52656A hydrochloride	Agonist	99.98%
ZT 52656A is a selective kappa opioid agonist, used for the prevention or alleviation of pain in the eye.

HY-123534A

CYT-1010 hydrochloride	Agonist
CYT-1010 hydrochloride is a mu-opioid receptor agonist extracted from patent WO2013173730A2, with EC₅₀s of 13.1 nM and 0.0053 nM on beta-arrestin recruitment and inhibition of cAMP production, respectively.

HY-19876

PL37	Agonist
PL37 (Debio-0827) is an orally active Enkephalinase dual inhibitor (dual inhibition refers to the simultaneous inhibition of Neutral Endopeptidase and Aminopeptidase N activities). PL37 exerts its anti-hyperalgesic effects by activating μ-opioid receptors (µ-opioid receptors), with an ED₅₀ value of 13.4 mg/kg for analgesic effects in mice. PL37 can be used to study diabetic neuropathic pain.

HY-113929R

Loperamide oxide (Standard)	Agonist
Loperamide oxide (Standard) is the analytical standard of Loperamide oxide. This product is intended for research and analytical applications. Loperamide oxide (R-58425) is a orally active prodrug of the Loperamide (HY-156131). Loperamide oxide incubation with the contents of the intestinal lumen inhibits fluid secretion under aerobic conditions.

HY-107747A

GR 89696 free base	Agonist
GR 89696 free base is a highly selective κ2 opioid receptor agonist with potential to prevent pruritus.

HY-P1338A

PL-017 TFA	Agonist
PL-017 TFA is a potent and selective μ opioid receptor agonist with an IC₅₀ of 5.5 nM for ¹²⁵I-FK 33,824 binding to μ site. PL-017 TFA produces long-lasting, reversible analgesia in rats.

HY-P0288A

[Leu5]-Enkephalin TFA	Agonist
[Leu5]-Enkephalin TFA is a pentapeptide with morphine like properties. [Leu5]-Enkephalin TFA is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.

HY-145128

GR103545	Agonist
GR103545 is a potent and selective agonist of the κ-opioid receptor (κ-OR). ¹¹GR103545 is a radiotracer for imaging κ-OR in vivo^[1]

Name
Email *

	Sorry, but the email address you supplied was invalid.